Johtajistomme
{{searchText ? ' for "' : ''}}{{searchText}}{{searchText ? '"' : ''}}
Scott Campbell
Senior Vice President, Regulatory and Clinical Affairs
Scott held progressive leadership roles, including Chief Regulatory Officer with global responsibility for Quality, Regulatory and Clinical Affairs in 2015. In 2017, following the Danaher (DHR) acquisition of Cepheid, Scott was named SVP and General Manager of Oncology, responsible for architecting the overall business unit vision, strategy, assay roadmap, and collaboration/M&A funnel. Toward the end of 2022, the Dx Platform leadership engaged Scott to come back to the Regulatory and Clinical Affairs teams.
Prior to Cepheid, Scott served in Director roles at Nanosphere, a Luminex company, in Clinical Affairs and Marketing, Nucleic Acids. Scott’s career in molecular diagnostics spans nearly 25 years with roles concentrated in clinical, regulatory, and commercial operations.
Scott earned a B.S. in Biology and M.S. in Botany at the University of Wyoming, and holds a Ph.D. in Cell, Molecular and Developmental Biology and an MBA, both from the University of California, Riverside.